A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers

A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers IntroductionIn the United States, the incidence of hepatocellular carcinoma (HCC) has tripled over the last two decades, while the 5‐year survival of patients with HCC has remained largely unchanged at <12% (El‐Serag, ). Patients with early stage HCC have multiple treatment options and the 5‐year survival for treated patients exceeds 60% (Bruix and Sherman, ). Five‐year survival for HCC cases that are diagnosed at a later (symptomatic) stage is between 0 and 10%. Early detection of HCC through surveillance is critical to reducing mortality.The target population for HCC surveillance are those patients with cirrhosis, since 80–90% of HCC cases occur in patients with cirrhosis. Six‐month ultrasonography is recommended (Bruix and Sherman, ), however, there is disagreement over the benefit of surveillance. In the United States, the majority of surveillance ultrasounds are performed at local hospitals with variable quality because ultrasonography is operator dependent, not sensitive in detecting early lesions and difficult to perform in obese patients. Serum α‐Fetoprotein (AFP) is a diagnostic HCC biomarker widely used to complement ultrasonography. The reported sensitivity for AFP varies between 41 and 100% and specificity between 70 and 95% in both diagnostic and screening settings and across a range of study designs (Gebo http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biometrics Wiley

A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers

Loading next page...
 
/lp/wiley/a-bayesian-screening-approach-for-hepatocellular-carcinoma-using-tr100RNS0v
Publisher
Wiley
Copyright
© 2018, The International Biometric Society
ISSN
0006-341X
eISSN
1541-0420
D.O.I.
10.1111/biom.12717
Publisher site
See Article on Publisher Site

Abstract

IntroductionIn the United States, the incidence of hepatocellular carcinoma (HCC) has tripled over the last two decades, while the 5‐year survival of patients with HCC has remained largely unchanged at <12% (El‐Serag, ). Patients with early stage HCC have multiple treatment options and the 5‐year survival for treated patients exceeds 60% (Bruix and Sherman, ). Five‐year survival for HCC cases that are diagnosed at a later (symptomatic) stage is between 0 and 10%. Early detection of HCC through surveillance is critical to reducing mortality.The target population for HCC surveillance are those patients with cirrhosis, since 80–90% of HCC cases occur in patients with cirrhosis. Six‐month ultrasonography is recommended (Bruix and Sherman, ), however, there is disagreement over the benefit of surveillance. In the United States, the majority of surveillance ultrasounds are performed at local hospitals with variable quality because ultrasonography is operator dependent, not sensitive in detecting early lesions and difficult to perform in obese patients. Serum α‐Fetoprotein (AFP) is a diagnostic HCC biomarker widely used to complement ultrasonography. The reported sensitivity for AFP varies between 41 and 100% and specificity between 70 and 95% in both diagnostic and screening settings and across a range of study designs (Gebo

Journal

BiometricsWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off